Present and Future Anticoagulants

It is estimated that between 500,000 and 2 million thromboembolic events occur annually in the United States, including deep venous thromboses, myocardial infarctions, thromboembolic strokes, and pulmonary emboli. Although major thrombi often can be lysed with fibrinolytic agents or sometimes can be removed surgically, pharmacologic prevention of thrombus formation in susceptible patients and high-risk situations is clearly preferable. Thus, anticoagulants and antiplatelet agents play a critical role in preventing thrombus formation associated with a variety of disease states, pathologic processes, and clinical situations (eg, thrombus formation on a prosthetic heart valve or in the left atrium of a patient who has atrial fibrillation; deep venous thrombosis [DVT] in the perioperative period after hip arthroplasty or knee replacement).

Marc E. Stone MD, Division of Cardiothoracic Anesthesiology, Mount Sinai School of Medicine, 1 Gustave L. Levy Place, Box 1010, New York, NY 10029, USA

Linda Shore-Lesserson MD, Cardiothoracic Anesthesiology, Montefiore Medical Center, 111 East 210th Street, Bronx, New York 10467, USA

Para continuar leyendo el artículo clikear aquí.

Para traducir el texto en inglés al español clikear aquí.

Fuente: Sciencedirect